<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31938860</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>08</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1459</ISSN><JournalIssue CitedMedium="Internet"><Volume>267</Volume><Issue>5</Issue><PubDate><Year>2020</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of neurology</Title><ISOAbbreviation>J Neurol</ISOAbbreviation></Journal><ArticleTitle>ALS-derived fibroblasts exhibit reduced proliferation rate, cytoplasmic TDP-43 aggregation and a higher susceptibility to DNA damage.</ArticleTitle><Pagination><StartPage>1291</StartPage><EndPage>1299</EndPage><MedlinePgn>1291-1299</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-020-09704-8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Dermic fibroblasts have been proposed as a potential genetic-ALS cellular model. This study aimed to explore whether dermic fibroblasts from patients with sporadic-ALS (sALS) recapitulate alterations typical of ALS motor neurons and exhibit abnormal DNA-damage response.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Dermic fibroblasts were obtained from eight sALS patients and four control subjects. Cellular characterization included proliferation rate analysis, cytoarchitecture studies and confocal immunofluorescence assessment for TDP-43. Additionally, basal and irradiation-induced DNA damage was evaluated by confocal immunofluorescence and biochemical techniques.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">sALS-fibroblasts showed decreased proliferation rates compared to controls. Additionally, whereas control fibroblasts exhibited the expected normal spindle-shaped morphology, ALS fibroblasts were thinner, with reduced cell size and enlarged nucleoli, with frequent cytoplasmic TDP-43aggregates. Also, baseline signs of DNA damage were evidenced more frequently in ALS-derived fibroblasts (11 versus 4% in control-fibroblasts). Assays for evaluating the irradiation-induced DNA damage demonstrated that DNA repair was defective in ALS-fibroblasts, accumulating more than double of &#x3b3;H2AX-positive DNA damage foci than controls. Very intriguingly, the proportion of fibroblasts particularly vulnerable to irradiation (with more than 15 DNA damage foci per nucleus) was seven times higher in ALS-derived fibroblasts than in controls.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Dermic-derived ALS fibroblasts recapitulate relevant cellular features of sALS and show a higher susceptibility to DNA damage and defective DNA repair responses. Altogether, these results support that dermic fibroblasts may represent a convenient and accessible ALS cellular model to study pathogenetic mechanisms, particularly those related to DNA damage response, as well as the eventual response to disease-modifying therapies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Riancho</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Service of Neurology, Hospital Sierrallana-IDIVAL, Barrio Ganzo s/n, 39300, Torrelavega, Spain. javier.riancho86@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine and Psychiatry, University of Cantabria, Santander, Spain. javier.riancho86@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n en Red de Enfermedades Neurodegenerativas, CIBERNED. Instituto Carlos III, Madrid, Spain. javier.riancho86@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castanedo-V&#xe1;zquez</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Service of Radiology, Hospital, Universitario Marqu&#xe9;s de Valdecilla, Santander, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gil-Bea</LastName><ForeName>Francisco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n en Red de Enfermedades Neurodegenerativas, CIBERNED. Instituto Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurosciences Area. Biodonostia Research Institute, San Sebasti&#xe1;n, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tapia</LastName><ForeName>Olga</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n en Red de Enfermedades Neurodegenerativas, CIBERNED. Instituto Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anatomy and Cell Biology, University of Cantabria-IDIVAL, Santander, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arozamena</LastName><ForeName>Jana</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Cell Biology, University of Cantabria-IDIVAL, Santander, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dur&#xe1;n-V&#xed;an</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Service of Dermatology, Hospital Universitario Marqu&#xe9;s de Valdecilla, Santander, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sedano</LastName><ForeName>Mar&#xed;a Jos&#xe9;</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n en Red de Enfermedades Neurodegenerativas, CIBERNED. Instituto Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Service of Neurology, Hospital Universitario Marqu&#xe9;s de Valdecilla-IDIVAL, Santander, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berciano</LastName><ForeName>Maria Teresa</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n en Red de Enfermedades Neurodegenerativas, CIBERNED. Instituto Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anatomy and Cell Biology, University of Cantabria-IDIVAL, Santander, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopez de Munain</LastName><ForeName>Adolfo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n en Red de Enfermedades Neurodegenerativas, CIBERNED. Instituto Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurosciences Area. Biodonostia Research Institute, San Sebasti&#xe1;n, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Service of Neurology, Hospital Universitario Donostia, San Sebasti&#xe1;n, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences. School of Medicine and Nursery, University of the Basque Country, San Sebasti&#xe1;n, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lafarga</LastName><ForeName>Miguel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n en Red de Enfermedades Neurodegenerativas, CIBERNED. Instituto Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anatomy and Cell Biology, University of Cantabria-IDIVAL, Santander, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>PI18/01066</GrantID><Agency>Instituto de Salud Carlos III</Agency><Country/></Grant><Grant><GrantID>2016-04</GrantID><Agency>CIBERNED</Agency><Country/></Grant><Grant><GrantID>BIO17/ND/023-BD</GrantID><Agency>BIOEF</Agency><Country/></Grant><Grant><GrantID>2017222027</GrantID><Agency>Eusko Jaurlaritza</Agency><Country/></Grant><Grant><GrantID>2015111122</GrantID><Agency>Eusko Jaurlaritza</Agency><Country/></Grant><Grant><GrantID>INNVAL 16/11</GrantID><Agency>IDIVAL</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>01</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Neurol</MedlineTA><NlmUniqueID>0423161</NlmUniqueID><ISSNLinking>0340-5354</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003593" MajorTopicYN="N">Cytoplasm</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004249" MajorTopicYN="N">DNA Damage</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066263" MajorTopicYN="N">Protein Aggregation, Pathological</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012867" MajorTopicYN="N">Skin</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">DNA-damage</Keyword><Keyword MajorTopicYN="N">Fibroblasts</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>12</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>1</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>1</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31938860</ArticleId><ArticleId IdType="doi">10.1007/s00415-020-09704-8</ArticleId><ArticleId IdType="pii">10.1007/s00415-020-09704-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Logroscino G, Traynor BJ, Hardiman O, Chio A, Mitchell D, Swingler RJ et al (2010) Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry 81(4):385&#x2013;390</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2009.183525</ArticleId></ArticleIdList></Reference><Reference><Citation>Riancho J, Lozano-Cuesta P, Santurtun A, Sanchez-Juan P, Lopez-Vega JM, Berciano J et al (2016) Amyotrophic lateral sclerosis in Northern Spain 40 years later: what has changed? Neurodegener Dis 16(5&#x2013;6):337&#x2013;341</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000445750</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown RH, Al CA (2017) Amyotrophic Lateral Sclerosis. N Engl J Med 377(2):162&#x2013;172</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId></ArticleIdList></Reference><Reference><Citation>Zufiria M, Gil-Bea FJ, Fernandez-Torron R, Poza JJ, Munoz-Blanco JL, Rojas-Garcia R et al (2016) ALS: a bucket of genes, environment, metabolism and unknown ingredients. Prog Neurobiol 142:104&#x2013;129</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2016.05.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Riancho J, Bosque-Varela P, Perez-Pereda S, Povedano M, de Munain AL, Santurtun A (2018) The increasing importance of environmental conditions in amyotrophic lateral sclerosis. Int J Biometeorol 62:1361&#x2013;1374</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00484-018-1550-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner LM, Halliday GM, Kril JJ, Gotz J, Hodges JR, Kiernan MC (2015) FTD and ALS&#x2013;translating mouse studies into clinical trials. Nat Rev Neurol 11(6):360&#x2013;366</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2015.65</ArticleId></ArticleIdList></Reference><Reference><Citation>Lutz C (2018) Mouse models of ALS: Past, present and future. Brain Res 1693(Pt A):1&#x2013;10</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2018.03.024</ArticleId></ArticleIdList></Reference><Reference><Citation>Picher-Martel V, Valdmanis PN, Gould PV, Julien JP, Dupre N (2016) From animal models to human disease: a genetic approach for personalized medicine in ALS. Acta Neuropathol Commun 4(1):70</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-016-0340-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Auburger G, Klinkenberg M, Drost J, Marcus K, Morales-Gordo B, Kunz WS et al (2012) Primary skin fibroblasts as a model of Parkinson's disease. Mol Neurobiol 46(1):20&#x2013;27</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-012-8245-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Linthout S, Miteva K, Tschope C (2014) Crosstalk between fibroblasts and inflammatory cells. Cardiovasc Res 102(2):258&#x2013;269</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvu062</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabatelli M, Zollino M, Conte A, Del Grande A, Marangi G, Lucchini M et al (2015) Primary fibroblasts cultures reveal TDP-43 abnormalities in amyotrophic lateral sclerosis patients with and without SOD1 mutations. Neurobiol Aging 36(5):2005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2015.02.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Imamura K, Izumi Y, Watanabe A, Tsukita K, Woltjen K, Yamamoto T et al (2017) The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis. Sci Transl Med 9:3962</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaf3962</ArticleId></ArticleIdList></Reference><Reference><Citation>Mata-Garrido J, Tapia O, Casafont I, Berciano MT, Cuadrado A, Lafarga M (2018) Persistent accumulation of unrepaired DNA damage in rat cortical neurons: nuclear organization and ChIP-seq analysis of damaged DNA. Acta Neuropathol Commun 6(1):68</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-018-0573-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow HM, Herrup K (2015) Genomic integrity and the ageing brain. Nat Rev Neurosci 16(11):672&#x2013;684</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn4020</ArticleId></ArticleIdList></Reference><Reference><Citation>Madabhushi R, Pan L, Tsai LH (2014) DNA damage and its links to neurodegeneration. Neuron 83(2):266&#x2013;282</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.06.034</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders LH, Laganiere J, Cooper O, Mak SK, Vu BJ, Huang YA et al (2014) LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson's disease patients: reversal by gene correction. Neurobiol Dis 62:381&#x2013;386</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2013.10.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovell MA, Markesbery WR (2007) Oxidative DNA damage in mild cognitive impairment and late-stage Alzheimer's disease. Nucleic Acids Res 35(22):7497&#x2013;7504</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkm821</ArticleId></ArticleIdList></Reference><Reference><Citation>Farg MA, Konopka A, Soo KY, Ito D, Atkin JD (2017) The DNA damage response (DDR) is induced by the C9orf72 repeat expansion in amyotrophic lateral sclerosis. Hum Mol Genet 26(15):2882&#x2013;2896</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddx170</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Hegde ML (2019) New mechanisms of DNA repair defects in fused in sarcoma-associated neurodegeneration: stage set for DNA repair-based therapeutics? J Exp Neurosci 13:1179069519856358</Citation><ArticleIdList><ArticleId IdType="pubmed">31217692</ArticleId><ArticleId IdType="pmc">6558540</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitra J, Guerrero EN, Hegde PM, Liachko NF, Wang H, Vasquez V et al (2019) Motor neuron disease-associated loss of nuclear TDP-43 is linked to DNA double-strand break repair defects. Proc Natl Acad Sci USA 116(10):4696&#x2013;4705</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1818415116</ArticleId></ArticleIdList></Reference><Reference><Citation>Naumann M, Pal A, Goswami A, Lojewski X, Japtok J, Vehlow A et al (2018) Impaired DNA damage response signaling by FUS-NLS mutations leads to neurodegeneration and FUS aggregate formation. Nat Commun 9(1):335</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-02299-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1(5):293&#x2013;299</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId></ArticleIdList></Reference><Reference><Citation>Vangipuram M, Ting D, Kim S, Diaz R, Schule B (2013) Skin punch biopsy explant culture for derivation of primary human fibroblasts. J Vis Exp 77:e3779</Citation></Reference><Reference><Citation>Mata-Garrido J, Casafont I, Tapia O, Berciano MT, Lafarga M (2016) Neuronal accumulation of unrepaired DNA in a novel specific chromatin domain: structural, molecular and transcriptional characterization. Acta Neuropathol Commun 4:41</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-016-0312-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Capetillo O, Lee A, Nussenzweig M, Nussenzweig A (2004) H2AX: the histone guardian of the genome. DNA Repair 3(8&#x2013;9):959&#x2013;967</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dnarep.2004.03.024</ArticleId></ArticleIdList></Reference><Reference><Citation>Delgado-Calle J, Arozamena J, Garcia-Renedo R, Garcia-Ibarbia C, Pascual-Carra MA, Gonzalez-Macias J et al (2011) Osteocyte deficiency in hip fractures. Calcif Tissue Int 89(4):327&#x2013;334</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00223-011-9522-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP, Brown RH Jr, Cleveland DW (2016) Decoding ALS: from genes to mechanism. Nature 539(7628):197&#x2013;206</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature20413</ArticleId></ArticleIdList></Reference><Reference><Citation>Casafont I, Bengoechea R, Tapia O, Berciano MT, Lafarga M (2009) TDP-43 localizes in mRNA transcription and processing sites in mammalian neurons. J Struct Biol 167(3):235&#x2013;241</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsb.2009.06.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Palanca A, Casafont I, Berciano MT, Lafarga M (2014) Reactive nucleolar and Cajal body responses to proteasome inhibition in sensory ganglion neurons. Biochim Biophys Acta 1842(6):848&#x2013;859</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2013.11.016</ArticleId></ArticleIdList></Reference><Reference><Citation>Panier S, Boulton SJ (2014) Double-strand break repair: 53BP1 comes into focus. Nat Rev Mol Cell Biol 15(1):7&#x2013;18</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm3719</ArticleId></ArticleIdList></Reference><Reference><Citation>Konrad C, Kawamata H, Bredvik KG, Arreguin AJ, Cajamarca SA, Hupf JC et al (2017) Fibroblast bioenergetics to classify amyotrophic lateral sclerosis patients. Mol Neurodegener 12(1):76</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-017-0217-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu WC, Liu T, Liu ZH, Deng M (2016) Detection the mutated protein aggregation and mitochondrial function in fibroblasts from amyotrophic lateral sclerosis patients with SOD1 gene mutations. Zhonghua Yi Xue Za Zhi 96(25):1982&#x2013;1986</Citation><ArticleIdList><ArticleId IdType="pubmed">27470954</ArticleId></ArticleIdList></Reference><Reference><Citation>Orru S, Coni P, Floris A, Littera R, Carcassi C, Sogos V et al (2016) Reduced stress granule formation and cell death in fibroblasts with the A382T mutation of TARDBP gene: evidence for loss of TDP-43 nuclear function. Hum Mol Genet 25(20):4473&#x2013;4483</Citation><ArticleIdList><ArticleId IdType="pubmed">28172957</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo BM, Di Fini F, Notaro A, Spataro R, Conforti FL, La BV (2017) ALS-related mutant FUS protein is mislocalized to cytoplasm and is recruited into stress granules of fibroblasts from asymptomatic FUS P525L mutation carriers. Neurodegener Dis 17(6):292&#x2013;303</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000480085</ArticleId></ArticleIdList></Reference><Reference><Citation>Alberts, Johnson, Lewis, Raf, Roberts, Walter (2015) Biolog&#xed;a molecular de la c&#xe9;lula. 6&#xaa; Edici&#xf3;n ed. Omega, Sabadell. ISBN: 9788428216388</Citation></Reference><Reference><Citation>Riancho J, Ruiz-Soto M, Villagra NT, Berciano J, Berciano MT, Lafarga M (2014) Compensatory motor neuron response to chromatolysis in the murine hSOD1(G93A) model of amyotrophic lateral sclerosis. Front Cell Neurosci 8:346</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2014.00346</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SM, Asress S, Hales CM, Gearing M, Vizcarra JC, Fournier CN et al. (2019) TDP-43 cytoplasmic inclusion formation is disrupted in C9orf72-associated amyotrophic lateral sclerosis/frontotemporal lobar degeneration. Brain Commun 1(1):fcz014.</Citation></Reference><Reference><Citation>Codron P, Cassereau J, Vourch P, Veyrat-Durebex C, Blasco H, Kane S et al (2018) Primary fibroblasts derived from sporadic amyotrophic lateral sclerosis patients do not show ALS cytological lesions. Amyotroph Lateral Scler Frontotemporal Degener 19:446&#x2013;456</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1431787</ArticleId></ArticleIdList></Reference><Reference><Citation>De Marco G, Lupino E, Calvo A, Moglia C, Buccinna B, Grifoni S et al (2011) Cytoplasmic accumulation of TDP-43 in circulating lymphomonocytes of ALS patients with and without TARDBP mutations. Acta Neuropathol 121(5):611&#x2013;622</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-010-0786-7</ArticleId></ArticleIdList></Reference><Reference><Citation>De Marco G, Lomartire A, Calvo A, Risso A, De Luca E, Mostert M et al (2017) Monocytes of patients with amyotrophic lateral sclerosis linked to gene mutations display altered TDP-43 subcellular distribution. Neuropathol Appl Neurobiol 43(2):133&#x2013;153</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12328</ArticleId></ArticleIdList></Reference><Reference><Citation>Casafont I, Palanca A, Lafarga V, Berciano MT, Lafarga M (2011) Effect of ionizing radiation in sensory ganglion neurons: organization and dynamics of nuclear compartments of DNA damage/repair and their relationship with transcription and cell cycle. Acta Neuropathol 122(4):481&#x2013;493</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0869-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Riancho J, Gil-Bea FJ, Castanedo-Vazquez D, Sedano MJ, Zufiria M, de Eulate GFG et al (2018) Clinical evidences supporting the Src/c-Abl pathway as potential therapeutic target in amyotrophic lateral sclerosis. J Neurol Sci 393:80&#x2013;82</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2018.08.013</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>